[go: up one dir, main page]

AU6568594A - Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells - Google Patents

Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells

Info

Publication number
AU6568594A
AU6568594A AU65685/94A AU6568594A AU6568594A AU 6568594 A AU6568594 A AU 6568594A AU 65685/94 A AU65685/94 A AU 65685/94A AU 6568594 A AU6568594 A AU 6568594A AU 6568594 A AU6568594 A AU 6568594A
Authority
AU
Australia
Prior art keywords
tranfer
peptides
nucleic acid
injecting
eucaryotic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65685/94A
Inventor
Jens Dannull
Gunther-Gerhard Jung
Karin Moelling
Andrej Surovoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU6568594A publication Critical patent/AU6568594A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU65685/94A 1993-04-14 1994-04-13 Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells Abandoned AU6568594A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4312131 1993-04-14
DE4312131 1993-04-14
DE4318470 1993-06-03
DE4318470 1993-06-03
PCT/EP1994/001147 WO1994023751A1 (en) 1993-04-14 1994-04-13 Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells

Publications (1)

Publication Number Publication Date
AU6568594A true AU6568594A (en) 1994-11-08

Family

ID=25924900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65685/94A Abandoned AU6568594A (en) 1993-04-14 1994-04-13 Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells

Country Status (3)

Country Link
EP (1) EP0693939A1 (en)
AU (1) AU6568594A (en)
WO (1) WO1994023751A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
AU5979296A (en) * 1995-06-07 1996-12-30 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6479464B1 (en) 1997-05-21 2002-11-12 Cobra Therapeutics Limited Compositions and methods for highly efficient transfection
GB9626539D0 (en) * 1996-12-20 1997-02-05 Univ Liverpool A method of enhancing the rate of transfection of cells
EP1007549B1 (en) * 1997-02-12 2006-12-27 Innovata Plc Compositions and methods for highly efficient transfection
WO2000011019A1 (en) * 1998-08-21 2000-03-02 Felix Frey Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
AU772847B2 (en) 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE50109166D1 (en) * 2000-06-28 2006-05-04 Max Delbrueck Centrum METHOD FOR IMPROVING TRANSFECTION EFFICIENCY
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7034109B2 (en) 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
EP2287341B1 (en) 2003-12-01 2013-02-13 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP2009526045A (en) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ Novel antimicrobial peptides and uses thereof
EP1844793A1 (en) * 2006-04-13 2007-10-17 D'Angelo, Sante Cyclic AMP binding molecule as vehicle for gene therapy
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3013353B1 (en) 2013-06-26 2021-04-21 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US20190315809A1 (en) * 2016-12-16 2019-10-17 Avixgen Inc Cytoplasmic transduction peptide and intracellular messenger comprising same
KR101933217B1 (en) 2017-12-28 2018-12-27 (주) 에빅스젠 Peptide for Inhibiting Skin Inflammation And Composition for Preventing or Treating Skin Inflammation Containing The Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
EP0537299A1 (en) * 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
KR100252547B1 (en) * 1991-09-05 2000-09-01 프레드 마리얀스키 Targeted Delivery of Poly- or Oligonucleotides to Cells
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus

Also Published As

Publication number Publication date
WO1994023751A1 (en) 1994-10-27
EP0693939A1 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
AU6568594A (en) Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
AU696381B2 (en) Detection of nucleic acids in cells by strand displacement amplification
AU5788994A (en) Nucleic acid pharmaceuticals
AU7225591A (en) Nucleic acid enzymes for cleaving dna
AU6623896A (en) Detection of nucleic acids and nucleic acid units
AU7032596A (en) Peptide nucleic acids and their effect on genetic material
AU6802994A (en) Nucleic acid analogue assay procedures
AU6191494A (en) Deoxyribonucleic acids
AU1565397A (en) Detection of differences in nucleic acids
AU4468696A (en) Conserved yeast nucleic acid sequences
AU1674697A (en) Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
AU7661794A (en) Reagents comprising chimeric molecules of nucleic acids and nucleic acid analogs
EP0544292A3 (en) Method of introduction of nucleic acids in cells
AU7680294A (en) Nucleic acid sequencing gels
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
AU4470789A (en) Compositions and process for amplyifying and detecting nucleic acid sequences
AU2986889A (en) Process of labeling specific chromosomes using recombinant repetitive dna
AU4077193A (en) Alpha-aminoboronic acid peptides and their use as elastase inhibitors
AU4135893A (en) Electrode for electrical cell fusion and electrical introduction of nucleic acids
AU7378196A (en) Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
AU7180294A (en) Reaction cell for protein sequencer and the like
AU8505898A (en) Nucleic acid compositions and methods of introducing nucleic acids into cells
AU4800793A (en) Electrophoresis of nucleic acid fragments
AU6714094A (en) Ocular delivery of nucleic acid
AU7617698A (en) Deoxyribonucleic acids containing inactivated hormone responsive elements